Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis

Sonya L. Heltshe, Christopher H. Goss, Valeria Thompson, Scott D. Sagel, Don B. Sanders, Bruce Marshall, Patrick A. Flume

Research output: Contribution to journalArticle

Abstract

Background Treatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score and time to next intravenous antibiotic therapy. Methods Data were used from a prospective observational study of patients with CF ≥10 years of age enrolled at six sites between 2007 and 2010. All were started on intravenous antibiotics for a clinically diagnosed PEx. Analysis of variance, logistic and Cox regression were used to examine the association of treatment factors with short-term and long-term clinical response. Results Of 123 patients with CF (60% women, aged 23.1±10.2 years), 33% experienced <10% relative improvement in FEV1 during treatment, which was associated with failing to recover baseline lung function 3 months after treatment (OR=7.8, 95% CI 1.9 to 31.6, p=0.004) and a longer time to next intravenous antibiotic (HR=0.48, 95% CI 0.27 to 0.85, p=0.011). Symptom improvement was observed but was not associated with subsequent lung function or time to next antibiotic therapy, which had a median recurrence time of 143 days. Conclusions Immediate symptomatic or respiratory response to PEx treatment did not have a clear relationship with subsequent outcomes such as lung function or intravenous antibiotic-free interval. These results can inform future research of treatment regimens for PEx in terms of interventions and outcome measures.

Original languageEnglish (US)
Pages (from-to)223-229
Number of pages7
JournalThorax
Volume71
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Cystic Fibrosis
Lung
Anti-Bacterial Agents
Therapeutics
Practice Management
Practice Guidelines
Observational Studies
Analysis of Variance
Logistic Models
Outcome Assessment (Health Care)
Prospective Studies
Pediatrics
Recurrence

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Heltshe, S. L., Goss, C. H., Thompson, V., Sagel, S. D., Sanders, D. B., Marshall, B., & Flume, P. A. (2016). Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 71(3), 223-229. https://doi.org/10.1136/thoraxjnl-2014-206750

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. / Heltshe, Sonya L.; Goss, Christopher H.; Thompson, Valeria; Sagel, Scott D.; Sanders, Don B.; Marshall, Bruce; Flume, Patrick A.

In: Thorax, Vol. 71, No. 3, 01.03.2016, p. 223-229.

Research output: Contribution to journalArticle

Heltshe, SL, Goss, CH, Thompson, V, Sagel, SD, Sanders, DB, Marshall, B & Flume, PA 2016, 'Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis', Thorax, vol. 71, no. 3, pp. 223-229. https://doi.org/10.1136/thoraxjnl-2014-206750
Heltshe, Sonya L. ; Goss, Christopher H. ; Thompson, Valeria ; Sagel, Scott D. ; Sanders, Don B. ; Marshall, Bruce ; Flume, Patrick A. / Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. In: Thorax. 2016 ; Vol. 71, No. 3. pp. 223-229.
@article{1472ea2c229f4705b6a00bb1f89ad4c7,
title = "Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis",
abstract = "Background Treatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score and time to next intravenous antibiotic therapy. Methods Data were used from a prospective observational study of patients with CF ≥10 years of age enrolled at six sites between 2007 and 2010. All were started on intravenous antibiotics for a clinically diagnosed PEx. Analysis of variance, logistic and Cox regression were used to examine the association of treatment factors with short-term and long-term clinical response. Results Of 123 patients with CF (60{\%} women, aged 23.1±10.2 years), 33{\%} experienced <10{\%} relative improvement in FEV1 during treatment, which was associated with failing to recover baseline lung function 3 months after treatment (OR=7.8, 95{\%} CI 1.9 to 31.6, p=0.004) and a longer time to next intravenous antibiotic (HR=0.48, 95{\%} CI 0.27 to 0.85, p=0.011). Symptom improvement was observed but was not associated with subsequent lung function or time to next antibiotic therapy, which had a median recurrence time of 143 days. Conclusions Immediate symptomatic or respiratory response to PEx treatment did not have a clear relationship with subsequent outcomes such as lung function or intravenous antibiotic-free interval. These results can inform future research of treatment regimens for PEx in terms of interventions and outcome measures.",
author = "Heltshe, {Sonya L.} and Goss, {Christopher H.} and Valeria Thompson and Sagel, {Scott D.} and Sanders, {Don B.} and Bruce Marshall and Flume, {Patrick A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1136/thoraxjnl-2014-206750",
language = "English (US)",
volume = "71",
pages = "223--229",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis

AU - Heltshe, Sonya L.

AU - Goss, Christopher H.

AU - Thompson, Valeria

AU - Sagel, Scott D.

AU - Sanders, Don B.

AU - Marshall, Bruce

AU - Flume, Patrick A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background Treatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score and time to next intravenous antibiotic therapy. Methods Data were used from a prospective observational study of patients with CF ≥10 years of age enrolled at six sites between 2007 and 2010. All were started on intravenous antibiotics for a clinically diagnosed PEx. Analysis of variance, logistic and Cox regression were used to examine the association of treatment factors with short-term and long-term clinical response. Results Of 123 patients with CF (60% women, aged 23.1±10.2 years), 33% experienced <10% relative improvement in FEV1 during treatment, which was associated with failing to recover baseline lung function 3 months after treatment (OR=7.8, 95% CI 1.9 to 31.6, p=0.004) and a longer time to next intravenous antibiotic (HR=0.48, 95% CI 0.27 to 0.85, p=0.011). Symptom improvement was observed but was not associated with subsequent lung function or time to next antibiotic therapy, which had a median recurrence time of 143 days. Conclusions Immediate symptomatic or respiratory response to PEx treatment did not have a clear relationship with subsequent outcomes such as lung function or intravenous antibiotic-free interval. These results can inform future research of treatment regimens for PEx in terms of interventions and outcome measures.

AB - Background Treatment of pulmonary exacerbations (PEx) in cystic fibrosis (CF) varies widely with no consensus on management practices or best indicators of therapeutic success. To design trials evaluating PEx treatment factors, we characterise the heterogeneity of PEx care in adults and paediatrics, and correlate it with measures of clinical response including short-term and long-term lung function changes, change in symptom severity score and time to next intravenous antibiotic therapy. Methods Data were used from a prospective observational study of patients with CF ≥10 years of age enrolled at six sites between 2007 and 2010. All were started on intravenous antibiotics for a clinically diagnosed PEx. Analysis of variance, logistic and Cox regression were used to examine the association of treatment factors with short-term and long-term clinical response. Results Of 123 patients with CF (60% women, aged 23.1±10.2 years), 33% experienced <10% relative improvement in FEV1 during treatment, which was associated with failing to recover baseline lung function 3 months after treatment (OR=7.8, 95% CI 1.9 to 31.6, p=0.004) and a longer time to next intravenous antibiotic (HR=0.48, 95% CI 0.27 to 0.85, p=0.011). Symptom improvement was observed but was not associated with subsequent lung function or time to next antibiotic therapy, which had a median recurrence time of 143 days. Conclusions Immediate symptomatic or respiratory response to PEx treatment did not have a clear relationship with subsequent outcomes such as lung function or intravenous antibiotic-free interval. These results can inform future research of treatment regimens for PEx in terms of interventions and outcome measures.

UR - http://www.scopus.com/inward/record.url?scp=84964380423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964380423&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2014-206750

DO - 10.1136/thoraxjnl-2014-206750

M3 - Article

C2 - 25911223

AN - SCOPUS:84964380423

VL - 71

SP - 223

EP - 229

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 3

ER -